244 related articles for article (PubMed ID: 25639903)
1. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.
Campos NG; Maza M; Alfaro K; Gage JC; Castle PE; Felix JC; Cremer ML; Kim JJ
Int J Cancer; 2015 Aug; 137(4):893-902. PubMed ID: 25639903
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador.
Campos NG; Maza M; Alfaro K; Gage JC; Castle PE; Felix JC; Masch R; Cremer M; Kim JJ
Int J Gynaecol Obstet; 2019 Apr; 145(1):40-46. PubMed ID: 30702142
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador.
Campos NG; Alfaro K; Maza M; Sy S; Melendez M; Masch R; Soler M; Conzuelo-Rodriguez G; Gage JC; Alonzo TA; Castle PE; Felix JC; Cremer M; Kim JJ
Prev Med; 2020 Feb; 131():105931. PubMed ID: 31765712
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of VIA and HPV detection as primary and sequential screening tests in a cervical cancer screening demonstration project in India.
Basu P; Mittal S; Banerjee D; Singh P; Panda C; Dutta S; Mandal R; Das P; Biswas J; Muwonge R; Sankaranarayanan R
Int J Cancer; 2015 Aug; 137(4):859-67. PubMed ID: 25631198
[TBL] [Abstract][Full Text] [Related]
6. Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador.
Cremer M; Maza M; Alfaro K; Morales Velado M; Felix J; Castle PE; Kim J; Gage JC
J Low Genit Tract Dis; 2017 Jan; 21(1):26-32. PubMed ID: 27922905
[TBL] [Abstract][Full Text] [Related]
7. Cervical Cancer Screening with Human Papillomavirus Self-Sampling Among Transgender Men in El Salvador.
Maza M; Meléndez M; Herrera A; Hernández X; Rodríguez B; Soler M; Alfaro K; Masch R; Conzuelo-Rodríguez G; Obedin-Maliver J; Cremer M
LGBT Health; 2020; 7(4):174-181. PubMed ID: 32407149
[No Abstract] [Full Text] [Related]
8. Introducing a High-Risk HPV DNA Test Into a Public Sector Screening Program in El Salvador.
Cremer ML; Maza M; Alfaro KM; Kim JJ; Ditzian LR; Villalta S; Alonzo TA; Felix JC; Castle PE; Gage JC
J Low Genit Tract Dis; 2016 Apr; 20(2):145-50. PubMed ID: 26890683
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
12. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
Campos NG; Castle PE; Wright TC; Kim JJ
Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
[TBL] [Abstract][Full Text] [Related]
14. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme.
Confortini M; Giorgi Rossi P; Barbarino P; Passarelli AM; Orzella L; Tufi MC
J Med Screen; 2010; 17(2):79-86. PubMed ID: 20660436
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
16. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil.
Vanni T; Legood R; Franco EL; Villa LL; Luz PM; Schwartsmann G
Int J Cancer; 2011 Aug; 129(3):671-9. PubMed ID: 20886598
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
20. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
